Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196799 | 0.85 | MEN1 (0.48) | KMT2AMEN1TSHRHSD11B1LMNA | |
| SCHEMBL28827166 | 0.85 | SRD5A2 (0.55) | KMT2AMEN1TSHRMAPK1NPSR1 | |
| SCHEMBL26402 | 0.83 | MEN1 (1.00) | KMT2AMEN1TSHRMAPK1HIF1A | |
| SCHEMBL4297794 | 0.83 | MEN1 (0.71) | KMT2AMEN1TSHRMAPK1HIF1A | |
| SCHEMBL19222956 | 0.83 | HSD11B1 (0.65) | KMT2AMEN1MAPK1POLBHSD11B1 | |
| SCHEMBL8743247 | 0.81 | KMT2A (0.68) | KMT2AMEN1TSHRMAPK1HIF1A | |
| SCHEMBL2860836 | 0.79 | TSHR (0.74) | KMT2AMEN1TSHRMAPK1HIF1A | |
| Phenaglycodol SCHEMBL259155 | 0.79 | MEN1 (0.65) | KMT2AMEN1TSHRMAPK1HIF1A | |
| SCHEMBL29092067 | 0.79 | MEN1 (0.65) | KMT2AMEN1TSHRMAPK1HIF1A | |
| SCHEMBL3855932 | 0.79 | MEN1 (0.65) | KMT2AMEN1TSHRMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405221-B2 | Substituted pyrimidines | MERCK & CO., INC. (US) | 2008-07-29 | — | — | US | claimed |
| US-20050245554-A1 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. | 2005-11-03 | — | — | US | claimed |
| US-20250066364-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2025-02-27 | — | — | US | disclosed |
| CN-114524776-B | Tetrazole compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2024-12-13 | — | — | CN | disclosed |
| CN-118930426-A | Method for preparing benzoic acid and derivatives thereof from tertiary alcohol | 中国科学院大连化学物理研究所 | 2024-11-12 | — | — | CN | disclosed |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| EP-4406616-A2 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2024-07-31 | — | — | EP | disclosed |
| EP-3215511-B1 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2024-04-17 | — | — | EP | disclosed |
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R & D Investments, S.A. (PT) | 2024-03-19 | — | — | US | disclosed |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| EP-4225730-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | The Regents of the University of California (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-0531715-A1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
| US-4742073-A | ANTIGLAUCOMA | BUNDGAARD HANS (DK) | 1988-05-03 | — | — | US | disclosed |
| US-4704452-A | YELLOW SHADES ON POLYESTERS | CIBA-GEIGY CORPORATION (US) | 1987-11-03 | — | — | US | disclosed |
| US-4700003-A | DISPERSION DYESTUFF INTERMEDIATES | CIBA-GEIGY CORPORATION (US) | 1987-10-13 | — | — | US | disclosed |
| EP-0186627-A2 | Orthonitroanilines and process for their preparation | CIBA-GEIGY AG (CH) | 1986-07-02 | — | — | EP | disclosed |
| EP-0185620-A2 | Monoazo compounds | CIBA-GEIGY AG (CH) | 1986-06-25 | — | — | EP | disclosed |
| EP-0106541-A2 | Pilocarpine prodrugs | Bundgaard, Hans (DK) | 1984-04-25 | — | — | EP | disclosed |
| US-4000269-A | ACARICIDES | AMERICAN CYANAMID COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
| US-3954876-A | HALOCUMENE OXIDATION CATALYZED BY METAL PHTHALOCYANINE COMPLEX | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | KMT2A 1425/4885MEN1 3796/4885TSHR 3417/4885 |
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | KMT2A 1241/4885MEN1 3247/4885TSHR 3964/4885 |
| US-20050245554-A1 | Substituted pyrimidines | CNR1, CNR2, GPR119 | KMT2A 3592/4885MEN1 627/4885TSHR 828/4885 |
| US-20250066364-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | KMT2A 1241/4885MEN1 3247/4885TSHR 3964/4885 |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | PRMT8, SIRT1, PRMT3 | KMT2A 270/4885MEN1 3785/4885TSHR 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.